Drug Type Small molecule drug |
Synonyms WX 390, WX-390, WXFL 10030390 + [1] |
Target |
Mechanism PI3K family inhibitors(Phosphatidylinositol 3-kinase family inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
STK11-mutant cancer | Phase 2 | CN | 25 Aug 2023 | |
Uterine Cervix Adenocarcinoma | Phase 2 | CN | 01 Aug 2023 | |
Lymphoma | Phase 2 | CN | 28 Oct 2022 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 03 Jun 2021 | |
PIK3CA positive Solid Tumors | Phase 2 | CN | 03 Jun 2021 | |
Endometrial Carcinoma | Phase 2 | CN | 19 Apr 2021 | |
Ovarian Cancer | Phase 2 | CN | 19 Apr 2021 | |
Advanced cancer | Phase 1 | CN | 25 Oct 2018 | |
PIK3CA mutation/HR-positive/HER2-negative Breast Cancer | IND Approval | CN | 17 Mar 2023 |
NCT06117540 (ESMO2024) Manual | Phase 2 | Neoplasms ARID1A Mutation | PIK3CA Mutation | 17 | bzidbrgbfr(fasticibsh) = ilzxrzuvgz vdyfkfejiz (xrdexzqlto ) View more | Positive | 14 Sep 2024 | |
WX390bo | bzidbrgbfr(fasticibsh) = kwyowgxnyq vdyfkfejiz (xrdexzqlto ) View more | ||||||
NCT06117566 (ESMO2024) Manual | Phase 1/2 | Advanced Cervical Carcinoma Second line | 24 | rqbjhnocqy(kgyjcauhho) = bvaqkabtxf kqubijgxws (msqksomtxg ) View more | Positive | 14 Sep 2024 | |
NCT06117566 (ESMO2024) Manual | Phase 1/2 | 65 | dlqvwpmidt(bqeqitszxv) = enkfrfixyp erdjsuvmit (etqnptyrub ) View more | Positive | 14 Sep 2024 | ||
qglkocleke(plrgfgckxi) = fjerfefyhv bdatxrmdzv (iemrpgejip ) View more | |||||||
Phase 1 | Solid tumor Treg | 18 | pilwarbsiv(jdhwzsniiz) = blgudcexeu kzkladshtx (otrzxhetll, 2.53 - 6.37) | Positive | 24 May 2024 | ||
Phase 1 | 25 | uvnftpsipe(rulmqgpriv) = gzohpoknti wootqysmnv (njjwvntlku ) View more | Positive | 20 May 2021 |